Clinical Trial Update: Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 dose-escalation study in HIV-infected patients using autologous T-cells edited at the CCR5 gene with zinc finger…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CCR5-edited autologous T-cells (ZFN)

Snippet

Sponsor: Sangamo Therapeutics | Conditions: HIV Infection, HIV Infections | Phase 1 | Status: COMPLETED